Symbol Lookup

Friday March 24, 2017 1:55 PM ET. Data delayed 15 minutes.
16.76
0.07 (0.42%)
Bid/Lots
16.74/1
Ask/Lots
16.80/8
Open/Prev Close
16.90/16.69
Day Range
16.50-17.23
52-Week Range
4.35-19.44
Vol/Avg Daily Vol
800.5K/1.9M

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Legal Cannabis Market Contributes to Tax Revenues
9:00AM ET on Monday Mar 20, 2017 by PR Newswire
Companies Mentioned: INSY, CIIX, GWPH, CARA, ZYNE

FinancialBuzz.com News Commentary

The fast-growing legal cannabis industry could become a major driver of the U.S. economy. According to a new report published by New Frontier Data, the legal cannabis market is projected to reach more than $24 billion by 2025, and generate $2.3 billion in state tax revenue from retail sales by 2020. Many states in the U.S. see significant economic benefits from legalizing cannabis. Colorado, where recreational cannabis has been legal since 2014, sold $1.3 billion of legal cannabis in 2016 and generated almost $200 million in tax revenue, according to the Colorado Department of Revenue tax data. The pace of cannabis legalization in the United States has accelerated and this could boost the economy, by creating more jobs and increasing state tax revenues. ChineseInvestors.com, Inc. (OTC: CIIX), Cara Therapeutics (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), GW Pharmaceuticals (NASDAQ: GWPH)

FinancialBuzz.com News Commentary

The fast-growing legal cannabis industry could become a major driver of the U.S. economy. According to a new report published by New Frontier Data, the legal cannabis market is projected to reach more th...

Mar 17, 2017

5 Biotech Companies Set for Major Breakouts in 2017
8:00AM ET on Friday Mar 17, 2017 by PR Newswire
Companies Mentioned: CLVS, BIIB, CARA, CELG

OilPrice.com News Commentary

There's nothing more potentially rewarding right now than a visionary biotech company, poised for explosive gains, on the basis of a ground-breaking drug, medical device or procedure.

OilPrice.com News Commentary

There's nothing more potentially rewarding right now than a visionary biotech company, poised for explosive gains, on the basis of a ground-breaking drug, medical device or procedure.

Mar 15, 2017

Legal Cannabis Sales Projected to Grow
9:00AM ET on Wednesday Mar 15, 2017 by PR Newswire
Companies Mentioned: INSY, CIIX, CNAB, CARA, MSRT

FinancialBuzz.com News Commentary

Over the years, many states have legalized the use of cannabis products, for both medical and recreational purposes. As a result sales of such products grew overtime, and a new industry has been established. A report published on March 9th by New Frontier Data, a technology-driven analytics company specializing in the cannabis industry, reveals that the legal cannabis market was worth an estimated $6.6 billion in 2016, and is projected to grow at a compound annual growth rate (CAGR) of 16% to reach more than $24 billion by 2025. The projections are being made under the assumption that no new states will pass legalization legislations throughout the forecasted period. ChineseInvestors.com, Inc. (OTC: CIIX), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), United Cannabis Corporation (OTC: CNAB), MassRoots Inc. (OTC: MSRT)

FinancialBuzz.com News Commentary

Over the years, many states have legalized the use of cannabis products, for both medical and recreational purposes. As a result sales of such products grew overtime, and a new industry has been establis...

Mar 13, 2017

BRIEF-Cara files for mixed shelf of up to $250.0 mln
4:53PM ET on Monday Mar 13, 2017 by Thomson Reuters
Companies Mentioned: CARA

March 13 (Reuters) - Cara Therapeutics Inc

* Files for mixed shelf of up to $250.0 million - sec filing Source text for Eikon: Further company coverage...

March 13 (Reuters) - Cara Therapeutics Inc

* Files for mixed shelf of up to $250.0 million - sec filing Source text for Eikon: Further company coverage...

Cara Therapeutics to Present at March Medical Meetings
4:30PM ET on Monday Mar 13, 2017 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it will present at two upcoming medical meetings.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...

← Newer123Older →

Peers Headlines

Mar 22, 2017

Mixed Marijuana Messages From Trump Administration Make Diversification Imperative
8:30AM ET on Wednesday Mar 22, 2017 by PR Newswire
Companies Mentioned: SING, CBIS, CIIX, MJNA, CRBP

NetworkNewsWire Editorial Coverage

Deciphering marijuana policy under the Trump Administration can be difficult, given differing statements by White House officials. Federal laws are at odds with a number of states that have legalized ma...

Mar 20, 2017

Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017
8:30AM ET on Monday Mar 20, 2017 by GlobeNewswire
Companies Mentioned: CRVS

Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present interim data from its ongoing Phase...

Mar 17, 2017

Analyst Actions: Wells Fargo Initiates Coverage on Lion Biotechnologies with Outperform Rating
8:11AM ET on Friday Mar 17, 2017 by MT Newswires
Companies Mentioned: LBIO
08:11 AM EDT, 03/17/2017 (MT Newswires) -- Lion Biotechnologies' (LBIO) average rating among analysts is a buy, with an average price target of $19. Price: 7.60, Change: +0.15, Percent Change: +2.01 ...

Mar 16, 2017

Karyopharm Therapeutics' Q4 Narrows to $0.65 Per Share Vs Yr Ago
8:09AM ET on Thursday Mar 16, 2017 by MT Newswires
Companies Mentioned: KPTI
08:09 AM EDT, 03/16/2017 (MT Newswires) -- Karyopharm Therapeutics (KPTI) said Thursday its Q4 loss was $0.65 per share, narrower compared with an $0.81 loss per share in the same period a year ago and slightly better than 10 analysts' expectatio...
BRIEF-Karyopharm reports Q4 loss of $0.65 per share
7:50AM ET on Thursday Mar 16, 2017 by Thomson Reuters
Companies Mentioned: KPTI

March 16 (Reuters) - Karyopharm Therapeutics Inc

* Karyopharm reports fourth quarter and full year 2016 financial results and provides Selinexor clinic...

Karyopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Update
7:30AM ET on Thursday Mar 16, 2017 by GlobeNewswire
Companies Mentioned: KPTI

ΓΆ?' Overall Response Rate of 28.4% Observed in Phase 2b SADAL Study in Relapsed/Refractory DLBCL; Additional Top-line Data to be Presented as a Late-Breaker at AACR 2017 Annual Meeting -

ΓΆ?' Company Announces FDA-Affirmed Development Pat...

Mar 13, 2017

BRIEF-Corvus Pharma to postpone R&D day due to anticipated severe winter storm
8:24AM ET on Monday Mar 13, 2017 by Thomson Reuters
Companies Mentioned: CRVS

March 13 (Reuters) - Corvus Pharmaceuticals Inc:

* Corvus Pharma - to postpone its research and development day scheduled for March 14 due to anticipat...

Corvus Pharmaceuticals to Reschedule R&D Day Due to Severe Winter Storm in the New York Tri-State Area
8:00AM ET on Monday Mar 13, 2017 by GlobeNewswire
Companies Mentioned: CRVS

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day scheduled for Ma...

Karyopharm Therapeutics Says FDA Places Selinexor Trials on Partial Clinical Hold
4:43AM ET on Monday Mar 13, 2017 by MT Newswires
Companies Mentioned: KPTI
04:43 AM EDT, 03/13/2017 (MT Newswires) -- Karyopharm Therapeutics (KPTI) said late Friday that the U.S. Food and Drug Administration has placed its clinical trials for selinexor across a variety of hematological and solid tumor malignancies on p...
Pre-Market Briefing: US Stock Futures Near Flat; Investors Eye Fed Rate Meeting, Dutch Election, Brexit
4:33AM ET on Monday Mar 13, 2017 by MT Newswires
Companies Mentioned: F, HSBC, BCS, KPTI, TACO, LEJU, BABA, HLTH, GNRT, ARLZ.ZY
04:33 AM EDT, 03/13/2017 (MT Newswires) -- US equities futures were barely changed early Monday as investors sat on the fence before a week of pivotal events. At home, monetary policy makers are largely expected to increase the interest rate afte...